Fibronectin as a Marker of Disease Severity in Critically Ill COVID-19 Patients
The SARS-CoV-2 virus alters the expression of genes for extracellular matrix proteins, including fibronectin. The aim of the study was to establish the relationship between different forms of fibronectin, such as plasma (pFN), cellular (EDA-FN), and proteolytic FN-fragments, and disease severity and...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-05-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/11/9/1566 |
| _version_ | 1797505290269097984 |
|---|---|
| author | Anna Lemańska-Perek Dorota Krzyżanowska-Gołąb Barbara Dragan Maciej Tyszko Barbara Adamik |
| author_facet | Anna Lemańska-Perek Dorota Krzyżanowska-Gołąb Barbara Dragan Maciej Tyszko Barbara Adamik |
| author_sort | Anna Lemańska-Perek |
| collection | DOAJ |
| description | The SARS-CoV-2 virus alters the expression of genes for extracellular matrix proteins, including fibronectin. The aim of the study was to establish the relationship between different forms of fibronectin, such as plasma (pFN), cellular (EDA-FN), and proteolytic FN-fragments, and disease severity and mortality of critically ill patients treated in the intensive care unit. The levels of pFN, EDA-FN, and FN-fragments were measured in patients with a viral (N = 43, COVID-19) or bacterial (N = 41, sepsis) infection, using immunoblotting and ELISA. The level of EDA-FN, but not pFN, was related to the treatment outcome and was significantly higher in COVID-19 Non-survivors than in Survivors. Furthermore, EDA-FN levels correlated with APACHE II and SOFA scores. FN-fragments were detected in 95% of COVID-19 samples and the amount was significantly higher in Non-survivors than in Survivors. Interestingly, FN-fragments were present in only 56% of samples from patients with bacterial sepsis, with no significant differences between Non-survivors and Survivors. The new knowledge gained from our research will help to understand the differences in immune response depending on the etiology of the infection. Fibronectin is a potential biomarker that can be used in clinical settings to monitor the condition of COVID-19 patients and predict treatment outcomes. |
| first_indexed | 2024-03-10T04:16:30Z |
| format | Article |
| id | doaj.art-e9e94f3c7260499bb86228d8910bd9c8 |
| institution | Directory Open Access Journal |
| issn | 2073-4409 |
| language | English |
| last_indexed | 2024-03-10T04:16:30Z |
| publishDate | 2022-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj.art-e9e94f3c7260499bb86228d8910bd9c82023-11-23T08:01:05ZengMDPI AGCells2073-44092022-05-01119156610.3390/cells11091566Fibronectin as a Marker of Disease Severity in Critically Ill COVID-19 PatientsAnna Lemańska-Perek0Dorota Krzyżanowska-Gołąb1Barbara Dragan2Maciej Tyszko3Barbara Adamik4Department of Chemistry and Immunochemistry, Wroclaw Medical University, M. Sklodowskiej-Curie 48/50, 50-369 Wroclaw, PolandDepartment of Chemistry and Immunochemistry, Wroclaw Medical University, M. Sklodowskiej-Curie 48/50, 50-369 Wroclaw, PolandClinical Department of Anesthesiology and Intensive Therapy, Wroclaw Medical University, Borowska 213, 50-556 Wroclaw, PolandClinical Department of Anesthesiology and Intensive Therapy, Wroclaw Medical University, Borowska 213, 50-556 Wroclaw, PolandClinical Department of Anesthesiology and Intensive Therapy, Wroclaw Medical University, Borowska 213, 50-556 Wroclaw, PolandThe SARS-CoV-2 virus alters the expression of genes for extracellular matrix proteins, including fibronectin. The aim of the study was to establish the relationship between different forms of fibronectin, such as plasma (pFN), cellular (EDA-FN), and proteolytic FN-fragments, and disease severity and mortality of critically ill patients treated in the intensive care unit. The levels of pFN, EDA-FN, and FN-fragments were measured in patients with a viral (N = 43, COVID-19) or bacterial (N = 41, sepsis) infection, using immunoblotting and ELISA. The level of EDA-FN, but not pFN, was related to the treatment outcome and was significantly higher in COVID-19 Non-survivors than in Survivors. Furthermore, EDA-FN levels correlated with APACHE II and SOFA scores. FN-fragments were detected in 95% of COVID-19 samples and the amount was significantly higher in Non-survivors than in Survivors. Interestingly, FN-fragments were present in only 56% of samples from patients with bacterial sepsis, with no significant differences between Non-survivors and Survivors. The new knowledge gained from our research will help to understand the differences in immune response depending on the etiology of the infection. Fibronectin is a potential biomarker that can be used in clinical settings to monitor the condition of COVID-19 patients and predict treatment outcomes.https://www.mdpi.com/2073-4409/11/9/1566COVID-19fibronectinintensive caremortality predictionbiomarkers |
| spellingShingle | Anna Lemańska-Perek Dorota Krzyżanowska-Gołąb Barbara Dragan Maciej Tyszko Barbara Adamik Fibronectin as a Marker of Disease Severity in Critically Ill COVID-19 Patients Cells COVID-19 fibronectin intensive care mortality prediction biomarkers |
| title | Fibronectin as a Marker of Disease Severity in Critically Ill COVID-19 Patients |
| title_full | Fibronectin as a Marker of Disease Severity in Critically Ill COVID-19 Patients |
| title_fullStr | Fibronectin as a Marker of Disease Severity in Critically Ill COVID-19 Patients |
| title_full_unstemmed | Fibronectin as a Marker of Disease Severity in Critically Ill COVID-19 Patients |
| title_short | Fibronectin as a Marker of Disease Severity in Critically Ill COVID-19 Patients |
| title_sort | fibronectin as a marker of disease severity in critically ill covid 19 patients |
| topic | COVID-19 fibronectin intensive care mortality prediction biomarkers |
| url | https://www.mdpi.com/2073-4409/11/9/1566 |
| work_keys_str_mv | AT annalemanskaperek fibronectinasamarkerofdiseaseseverityincriticallyillcovid19patients AT dorotakrzyzanowskagołab fibronectinasamarkerofdiseaseseverityincriticallyillcovid19patients AT barbaradragan fibronectinasamarkerofdiseaseseverityincriticallyillcovid19patients AT maciejtyszko fibronectinasamarkerofdiseaseseverityincriticallyillcovid19patients AT barbaraadamik fibronectinasamarkerofdiseaseseverityincriticallyillcovid19patients |